Angelini Ventures Invests into €11.25 Million Seed Round for Elkedonia to Advance Neuroplastogens as Novel Therapeutics for Depression and Neuropsychiatric Disorders
Rome, Italy, 11th June 2025 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and Digital Health, announces its investment in Elkedonia SAS (Strasbourg, France), a pioneering biotech company developing a first-in-class neuroplastogen for the treatment of depression and other neuropsychiatric disorders. This €11.25 million seed round was co-led by Kurma Partners, WE Life Sciences and Bpifrance, with participation from Angelini Ventures, Argobio, Carma Fund, Capital Grand Est and Sambrinvest.
The funds raised will be used to advance Elkedonia's novel neuroplastogen approach to identify and optimize drug-like small molecule inhibitors of Elk1, a novel intracellular target previously considered to be "undruggable". Elk1 plays a pivotal role in reward brain circuits and neuroplasticity. These mechanisms are often altered in conditions like depression, Post-Traumatic Stress Disorder (PTSD), and addiction, making them chronic instead of transient. Preclinical and clinical studies suggest that Elk1 inhibition offers a promising and differentiated new approach to treating treatment-resistant depression, with rapid efficacy and without the side effects of psychedelics or ketamine derivatives, such as sedation, dependence, or hallucinations. Part of the financing will be directed toward biomarker research and validation efforts, supporting a precision-based therapeutic strategy.
This scientific and commercial potential was identified early by Argobio, which selected and developed Elkedonia within its venture studio. Founded in Paris and backed by leading investors including Angelini Ventures, Argobio partners with European academic institutions to transform early-stage discoveries into biotech companies, with a focus on rare diseases, neuroscience, oncology and immunology.Elkedonia is the first of these ventures to reach a significant financing milestone — a clear validation of Argobio's model and approach. This strong European investor syndicate reflects both the confidence of Argobio's founding investors in its model and Elkedonia's ability to attract leading life sciences investors at the seed stage. Building on this momentum, Argobio continues to expand its portfolio with the ambition to scale a repeatable model of biotech creation, driven by scientific excellence, entrepreneurial leadership and long-term investor alignment.
'We are excited to support Elkedonia's groundbreaking work in advancing neuroplastogens, which represents a potential first-in-class approach to treating depression,' said Fabrizio Calisti, Medical Director at Angelini Ventures. 'The novel nature of Elkedonia's target Elk1, previously thought to be undruggable, sets the company apart in the landscape of depression treatments, and we are proud to be part of this transformative journey. This investment reflects Angelini Ventures' commitment to supporting the exciting science coming out of European academic laboratories at the earliest stages via Argobio and subsequently providing further capital through our venture fund to accelerate the translation of cutting-edge research into therapies with the potential to transform outcomes for people with neuropsychiatric disorders.'
Fabrizio Calisti, M.D., Medical Director at Angelini Ventures, will join Elkedonia's Board of Directors.
'I am thrilled to welcome our founding seed investors and thank my colleagues at Argobio for their support in creating Elkedonia. The novelty of our neuroplastogen approach offers a strong value proposition supported by groundbreaking neuroscience research. We are positioned to make a significant impact on the treatment of major depressive disorders, bringing relief to all patients, including young people, adolescents and the elderly,' said Delphine Charvin, Chief Executive Officer and Co-Founder of Elkedonia, previously Operating Partner at Argobio. 'In addition, our development of biomarkers will allow us to pursue a precision medicine for patient selection and treatment efficacy monitoring.'
***
Notes to EditorsAbout Angelini Ventures
Angelini Ventures, the venture capital arm of Angelini Industries, is a Series A and Series B investment firm focused on accelerating disruptive innovations and trends in BioTech and Digital Health. Angelini Ventures will invest €300 million across a global portfolio in Europe and North America, drawing on a global team, strategic advisors and partners to help entrepreneurs scale their businesses into transformative category-leading companies.
To date, Angelini Ventures has invested around €100 million into 21 companies covering a range of therapeutic areas and modalities. Angelini Ventures' BioTech portfolio includes Therini Bio, Nuevocor, Neumirna, Cour Pharmaceuticals, Nouscom, Pretzel Therapeutics and Freya Biosciences. The Company's Digital Health portfolio includes Vantis Health, Avation, Cadence Neuroscience, Nobi, Noctrix and Serenis. www.angeliniventures.com
About Angelini Industries
Angelini Industries is a multinational industrial group founded in Ancona in 1919 by Francesco Angelini. Today, Angelini Industries represents a solid and diversified industrial reality that employs approximately 5,800 employees and operates in 21 countries around the world with revenues of over two billion euros, generated in the health, industrial technology and consumer goods sectors. A targeted investment strategy for growth, constant commitment to research and development, deep knowledge of markets and business sectors, make Angelini Industries one of the Italian companies of excellence in the sectors in which it operates.www.angeliniindustries.com
About Elkedonia Elkedonia is a Franco-Belgian start-up company dedicated to transforming the treatment of mental health disorders. Elkedonia is introducing a first-in-class antidepressant approach that leverages precision medicine. The lead discovery program targets the inhibition of the intracellular Elk1 protein to address the needs of treatment-resistant depression (TRD).www.elkedonia.com
About ArgobioArgobio is an international biotech start-up studio committed to turning cutting-edge innovations into breakthrough biotech companies. The studio sources early-stage therapeutic projects from leading European academic research institutions, focusing on rare diseases, neurological disorders, oncology, and immunology. By selecting and incubating these projects, Argobio aims to develop them into fully-fledged biotech companies, advancing them to significant Seed or Series A financing. With a team of highly experienced biotech entrepreneurs, the studio offers extensive expertise in novel drug discovery and development.www.argobiostudio.com
ContactsAngelini VenturesMartina Palmese, Communications Coordinatormartina.palmese@angeliniventures.com
Media contacts for Italy - SEC Newgate ItaliaDaniele Pinosa, daniele.pinosa@secnewgate.it; Tel. +39 3357233872Fausta Tagliarini; fausta.tagliarini@secnewgate.it; Tel. +39 3476474513Daniele Murgia; daniele.murgia@secnewgate.it; Tel. +39 3384330031
Media contacts outside Italy - MEDiSTRAVA Sylvie Berrebi, Sandi Greenwood, Mark Swallowangeliniventures@medistrava.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
27 minutes ago
- Wall Street Journal
EU Confirms Further One-Year Delay to Bank Trading Desk Rules
The European Union confirmed the delay by one more year of tougher global rules for banks' trading businesses. The bloc is seeking to level the playing field for European lenders amid U.S. President Trump's deregulation push. The region is home to BNP Paribas and Deutsche Bank, whose investment-bank trading desks could stand at a disadvantage if they have to comply with the rules ahead of their competitors across the Atlantic.
Forbes
27 minutes ago
- Forbes
AI Will Provide Much Needed Shortcut In Finding Earthlike Exoplanets
In the search for earthlike planets, AI is playing more and more of a role. But first one must define what is meant by earthlike. That's not an easy definition and is the cause of much confusion in the mainstream media. When planetary scientists say that a planet is earthlike, they really mean it's an earth mass planet that lies in the so-called habitable zone of any given extrasolar planetary system. That's loosely defined as the zone in which a given planet can harbor liquid water at its surface. But there's no guarantee that it has oceans, beaches, fauna, flora, or anything approaching life. Yet Jeanne Davoult, a French astrophysicist at the German Aerospace Center (DLR) in Berlin, is at the vanguard of using artificial intelligence to speed up the process of finding earthlike planets using AI modeling and algorithms that would boggle the minds of mere mortals. In a recent paper, appearing in the journal Astronomy & Astrophysics, Davoult, the paper's lead author writes that the aim is to use AI to predict which stars are most likely to host an earthlike planet. The goal is use AI to avoid blind searches, minimize detection times, and thus maximize the number of detections, she and colleagues at the University of Bern write. Using a previous study on correlations between the presence of an earthlike planet and the properties of its system, we trained an AI Random Forest, a machine learning algorithm, to recognize and classify systems as 'hosting an earthlike planet' or 'not hosting an earthlike planet,' the authors write. For planetary detection, we try to identify patterns in data sets, and patterns which correspond to planets, Davoult tells me via telephone. Understanding and anticipating where earthlike planets form first, and thus targeting observations to avoid blind searches, minimizes the average observation time for detecting an earthlike planets and maximizes the number of detections, the authors write. But among the estimated 6000 exoplanets thus detected in the last 30 years, only some 20 systems with at least one earthlike planet have been found, says Davoult. In fact, stars smaller than the Sun --- such as K-spectral type dwarfs as well as the ubiquitous red dwarf M-spectral type stars which make up most of the stars in the cosmos, all have longer lifetimes than our own G-spectral type star. Thus, because of their long stellar lifetimes, it's probably more likely for intelligent life to develop around these K and M types of stars, says Davoult. We are also focusing a lot on M dwarfs because it's easier to detect an earthlike planet around the stars than around sun like stars, because the habitable zone is closer to the stars, so the orbital period is shorter, she says. The three populations of synthetic systems used in this study differ only in the mass of the central star, the authors write. This single difference directly influences the mass of the protoplanetary disk and thus the amount of material available for planet formation, note the authors. As a result, the three populations exhibit different occurrences and properties for the same type of planet, highlighting the importance of studying various types of stars, they write. We have developed a model using a Random Forest Classifier to predict which known planetary systems are most likely to host an earthlike planet, the authors write. It's hard to really compare synthetic planetary populations and real planetary populations, because we know that our model is not perfect, says Davoult. But if you just take the big pattern at the system level, then I'm convinced it's a very powerful tool, she says. If we observe a planet within a given solar system, it doesn't mean that we've detected all the planets in this planetary system, says Davoult. That's because an earthlike planet might be a bit too far away from the star, or too small to detect, she says. In contrast, my model takes what we already know about planetary system and tells us if there is a possibility for an undetected earthlike planet to exist in the same planetary system, says Davoult. Davoult is specifically looking for terrestrial planets in the habitable zone of their parent stars. The very first step is just to detect them and create a database of earthlike planets, even if we have no clue about the composition of their atmospheres, says Davoult.
Bloomberg
31 minutes ago
- Bloomberg
Europe's Nuclear Ambitions Face €241 Billion Funding Challenge
The European Union's ambition to scale up nuclear energy as part of its 2050 climate neutrality goal will cost €241 billion ($280 billion), posing funding challenges, according to a draft document. More than four-fifths of investment under that base-case scenario would go on building new reactors, taking the bloc's capacity to 109 gigawatts by 2050, according to a draft of the European Commission's Nuclear Illustrative Program seen by Bloomberg News.
